165 related articles for article (PubMed ID: 20629598)
1. Prasugrel versus clopidogrel in Asian patients with acute coronary syndromes: design and rationale of a multi-dose, pharmacodynamic, phase 3 clinical trial.
Ge J; Zhu J; Hong BK; Boonbaichaiyapruck S; Goh YS; Hou CJ; Pinton P
Curr Med Res Opin; 2010 Sep; 26(9):2077-85. PubMed ID: 20629598
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
[TBL] [Abstract][Full Text] [Related]
3. Review of prasugrel for the secondary prevention of atherothrombosis.
Spinler SA; Rees C
J Manag Care Pharm; 2009 Jun; 15(5):383-95. PubMed ID: 19496635
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.
Small DS; Payne CD; Kothare P; Yuen E; Natanegara F; Teng Loh M; Jakubowski JA; Richard Lachno D; Li YG; Winters KJ; Farid NA; Ni L; Salazar DE; Tomlin M; Kelly R
Clin Ther; 2010 Feb; 32(2):365-79. PubMed ID: 20206794
[TBL] [Abstract][Full Text] [Related]
5. Prasugrel 5 mg in the very elderly attenuates platelet inhibition but maintains noninferiority to prasugrel 10 mg in nonelderly patients: the GENERATIONS trial, a pharmacodynamic and pharmacokinetic study in stable coronary artery disease patients.
Erlinge D; Gurbel PA; James S; Lindahl TL; Svensson P; Ten Berg JM; Foley DP; Wagner H; Brown PB; Luo J; Zhou C; Moser BA; Jakubowski JA; Small DS; Winters KJ; Angiolillo DJ
J Am Coll Cardiol; 2013 Aug; 62(7):577-83. PubMed ID: 23747759
[TBL] [Abstract][Full Text] [Related]
6. Transferring from clopidogrel loading dose to prasugrel loading dose in acute coronary syndrome patients. High on-treatment platelet reactivity analysis of the TRIPLET trial.
Diodati JG; Saucedo JF; Cardillo TE; Jakubowski JA; Henneges C; Effron MB; Lipkin FR; Walker JR; Duvvuru S; Sundseth SS; Fisher HN; Angiolillo DJ
Thromb Haemost; 2014 Aug; 112(2):311-22. PubMed ID: 24718367
[TBL] [Abstract][Full Text] [Related]
7. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study.
Montalescot G; Sideris G; Cohen R; Meuleman C; Bal dit Sollier C; Barthélémy O; Henry P; Lim P; Beygui F; Collet JP; Marshall D; Luo J; Petitjean H; Drouet L
Thromb Haemost; 2010 Jan; 103(1):213-23. PubMed ID: 20062936
[TBL] [Abstract][Full Text] [Related]
8. Effect on platelet reactivity from a prasugrel loading dose after a clopidogrel loading dose compared with a prasugrel loading dose alone: Transferring From Clopidogrel Loading Dose to Prasugrel Loading Dose in Acute Coronary Syndrome Patients (TRIPLET): a randomized controlled trial.
Diodati JG; Saucedo JF; French JK; Fung AY; Cardillo TE; Henneges C; Effron MB; Fisher HN; Angiolillo DJ
Circ Cardiovasc Interv; 2013 Oct; 6(5):567-74. PubMed ID: 24065443
[TBL] [Abstract][Full Text] [Related]
9. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
Zeymer U; Mochmann HC; Mark B; Arntz HR; Thiele H; Diller F; Montalescot G; Zahn R
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919
[TBL] [Abstract][Full Text] [Related]
10. Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Norgard NB; Abu-Fadel M
Vasc Health Risk Manag; 2009; 5():873-82. PubMed ID: 19898643
[TBL] [Abstract][Full Text] [Related]
11. Discharge aspirin dose and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel: an analysis from the TRITON-TIMI 38 study (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38).
Kohli P; Udell JA; Murphy SA; Cannon CP; Antman EM; Braunwald E; Wiviott SD
J Am Coll Cardiol; 2014 Jan; 63(3):225-32. PubMed ID: 24140678
[TBL] [Abstract][Full Text] [Related]
12. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the importance of CYP2C19*2 genotyping.
Alexopoulos D; Dimitropoulos G; Davlouros P; Xanthopoulou I; Kassimis G; Stavrou EF; Hahalis G; Athanassiadou A
JACC Cardiovasc Interv; 2011 Apr; 4(4):403-10. PubMed ID: 21511219
[TBL] [Abstract][Full Text] [Related]
13. Critical review of prasugrel for formulary decision makers.
Schafer JA; Kjesbo NK; Gleason PP
J Manag Care Pharm; 2009 May; 15(4):335-43. PubMed ID: 19422273
[TBL] [Abstract][Full Text] [Related]
14. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial.
Wiviott SD; Antman EM; Winters KJ; Weerakkody G; Murphy SA; Behounek BD; Carney RJ; Lazzam C; McKay RG; McCabe CH; Braunwald E;
Circulation; 2005 Jun; 111(25):3366-73. PubMed ID: 15967851
[TBL] [Abstract][Full Text] [Related]
15. A multiple dose study of prasugrel (CS-747), a novel thienopyridine P2Y12 inhibitor, compared with clopidogrel in healthy humans.
Jakubowski JA; Matsushima N; Asai F; Naganuma H; Brandt JT; Hirota T; Freestone S; Winters KJ
Br J Clin Pharmacol; 2007 Apr; 63(4):421-30. PubMed ID: 17076696
[TBL] [Abstract][Full Text] [Related]
16. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial.
Wiviott SD; Trenk D; Frelinger AL; O'Donoghue M; Neumann FJ; Michelson AD; Angiolillo DJ; Hod H; Montalescot G; Miller DL; Jakubowski JA; Cairns R; Murphy SA; McCabe CH; Antman EM; Braunwald E;
Circulation; 2007 Dec; 116(25):2923-32. PubMed ID: 18056526
[TBL] [Abstract][Full Text] [Related]
17. Decrease in high on-treatment platelet reactivity (HPR) prevalence on switching from clopidogrel to prasugrel: insights from the switching anti-platelet (SWAP) study.
Saucedo JF; Angiolillo DJ; DeRaad R; Frelinger AL; Gurbel PA; Costigan TM; Jakubowski JA; Ojeh CK; Duvvuru S; Effron MB;
Thromb Haemost; 2013 Feb; 109(2):347-55. PubMed ID: 23223867
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of adjusted-dose prasugrel compared with clopidogrel in Japanese patients with acute coronary syndrome: the PRASFIT-ACS study.
Saito S; Isshiki T; Kimura T; Ogawa H; Yokoi H; Nanto S; Takayama M; Kitagawa K; Nishikawa M; Miyazaki S; Nakamura M
Circ J; 2014; 78(7):1684-92. PubMed ID: 24759796
[TBL] [Abstract][Full Text] [Related]
19. Comparison of prasugrel and clopidogrel reloading on high platelet reactivity in clopidogrel-loaded patients undergoing percutaneous coronary intervention (PRAISE-HPR): a study protocol for a prospective randomized controlled clinical trial.
Lee DH; Kim MH; Park TH; Park JS; Park K; Zhang HZ; Seo JM; Lee MS
Trials; 2013 Feb; 14():62. PubMed ID: 23448344
[TBL] [Abstract][Full Text] [Related]
20. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial.
Montalescot G; Wiviott SD; Braunwald E; Murphy SA; Gibson CM; McCabe CH; Antman EM;
Lancet; 2009 Feb; 373(9665):723-31. PubMed ID: 19249633
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
